A-63162, A POTENT ORALLY ACTIVE INHIBITOR OF 5-LIPOXYGENASE (5-LO)

被引：0
|
作者：
CARTER, GW [1 ]
YOUNG, PR [1 ]
DYER, R [1 ]
ALBERT, DH [1 ]
BOUSKA, J [1 ]
BARLOW, J [1 ]
ROBERTS, E [1 ]
SONSALLA, J [1 ]
SUMMERS, J [1 ]
BROOKS, D [1 ]
机构：
[1] ABBOTT LABS, N CHICAGO, IL 60064 USA
来源：
FASEB JOURNAL | 1988年 / 2卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A1263 / A1263
页数：1
相关论文
共 50 条
  • [41] RWJ 63556, a potent, orally active dual 5-LO/COX-2 inhibitor: In vitro and in vivo pharmacology.
    Malloy, EA
    Beers, SA
    Wachter, M
    Wu, W
    Argentieri, D
    Steber, M
    Singer, M
    Ansell, J
    Ritchie, D
    Kirchner, T
    Barbone, A
    Aparicio, B
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 91 - MEDI
  • [42] CGS-22745, A NEW 5-LIPOXYGENASE (5-LO) INHIBITOR - HPLC METHOD AND PK/PD CHARACTERISTICS IN RATS AND DOGS
    CHOVAN, JP
    VERMEULEN, JD
    KIMBLE, EF
    MILLER, D
    WHITE, D
    ROLAND, DM
    ROBERTSON, P
    TRIPP, SL
    DUNTON, AW
    FASEB JOURNAL, 1991, 5 (06): : A1566 - A1566
  • [43] CONVERSION OF A CYCLOOXYGENASE (CO) INHIBITOR INTO A 5-LIPOXYGENASE (LO) INHIBITOR - A GENERAL-ROUTE TO NOVEL ORALLY ACTIVE ANTIINFLAMMATORY AND ANTIALLERGY DRUGS
    KREFT, AF
    FAILLI, AA
    MUSSER, JH
    KUBRAK, DM
    BANKER, AL
    STEFFAN, R
    DEMERSON, CA
    NELSON, JA
    SHAH, US
    GRAY, W
    MARSHALL, LA
    HOLLOWAY, D
    STURM, R
    CARLSON, RP
    BERKENKOPF, J
    GRIMES, D
    WEICHMAN, BM
    CHANG, JY
    DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 1991, 17 (08) : 381 - 387
  • [44] Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase
    Mano, T
    Stevens, RW
    Ando, K
    Nakao, K
    Okumura, Y
    Sakakibara, M
    Okumura, T
    Tamura, T
    Miyamoto, K
    BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (18) : 3879 - 3887
  • [45] METHOXYALKYL THIAZOLES - A NOVEL SERIES OF POTENT, ORALLY ACTIVE AND ENANTIOSELECTIVE INHIBITORS OF 5-LIPOXYGENASE
    MCMILLAN, RM
    BIRD, TGC
    CRAWLEY, GC
    EDWARDS, MP
    GIRODEAU, JM
    KINGSTON, JF
    FOSTER, SJ
    AGENTS AND ACTIONS, 1991, 34 (1-2): : 110 - 112
  • [46] Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors
    Frenette, R
    Hutchinson, JH
    Léger, S
    Thérien, M
    Brideau, C
    Chan, CC
    Charleson, S
    Ethier, D
    Guay, J
    Jones, TR
    McAuliffe, M
    Piechuta, H
    Riendeau, D
    Tagari, P
    Girard, Y
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (16) : 2391 - 2396
  • [47] The role of human 5-Lipoxygenase (5-LO) in carcinogenesis - a question of canonical and non-canonical functions
    Astrid S. Kahnt
    Ann-Kathrin Häfner
    Dieter Steinhilber
    Oncogene, 2024, 43 : 1319 - 1327
  • [48] INHIBITION OF LEUKOTRIENE BIOSYNTHESIS BY 5-LIPOXYGENASE (5-LO) ACTIVATION INHIBITORS, ACTIVE-SITE INHIBITORS AND COMPOUNDS WITH BOTH ACTIVITIES
    BELL, RL
    MAJEST, S
    BROOKS, DW
    WRIGHT, B
    OTIS, E
    LANNI, C
    CARTER, GW
    FASEB JOURNAL, 1992, 6 (04): : A1564 - A1564
  • [49] PHARMACOLOGICAL CHARACTERIZATION OF WAY-121,520 - A POTENT ANTIINFLAMMATORY INDOMETHACIN-BASED INHIBITOR OF 5-LIPOXYGENASE (5-LO) PHOSPHOLIPASE A(2) (PLA2)
    GLASER, KB
    CARLSON, RP
    SUNG, A
    BAUER, J
    LOCK, YW
    HOLLOWAY, D
    STURM, R
    HARTMAN, D
    WALTER, T
    WOEPPEL, S
    HOWELL, R
    GRAY, W
    GRIMES, D
    KUBRAK, D
    BANKER, A
    KREFT, A
    WEICHMAN, BM
    AGENTS AND ACTIONS, 1993, 39 : C30 - C32
  • [50] The role of human 5-Lipoxygenase (5-LO) in carcinogenesis - a question of canonical and non-canonical functions
    Kahnt, Astrid S.
    Haefner, Ann-Kathrin
    Steinhilber, Dieter
    ONCOGENE, 2024, 43 (18) : 1319 - 1327
12345